Subcutaneous efalizumab is not effective in the treatment of alopecia areata
VH Price, MK Hordinsky, EA Olsen, JL Roberts… - Journal of the American …, 2008 - Elsevier
BACKGROUND: Alopecia areata (AA) is a T-cell–mediated autoimmune disease.
Efalizumab is a T-cell–targeted therapy approved for the treatment of psoriasis. OBJECTIVE:
To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA.
METHODS: Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The
trial consisted of three 12-week periods—a double-blind treatment period, an open-label
efalizumab treatment period, and a safety follow-up. RESULTS: There were no statistical …
Efalizumab is a T-cell–targeted therapy approved for the treatment of psoriasis. OBJECTIVE:
To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA.
METHODS: Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The
trial consisted of three 12-week periods—a double-blind treatment period, an open-label
efalizumab treatment period, and a safety follow-up. RESULTS: There were no statistical …
